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Warfarin for Prevention of Ischemic Stroke Recurrence? 
Clinical Question 
Does anticoagulation with warfarin (Coumadin) prevent stroke recurrence in a patient with a 
history of noncardioembolic ischemic stroke? 
Evidence-Based Answer 
There is no evidence that anticoagulation with warfarin, initiated after a noncardioembolic 
ischemic stroke, significantly reduces stroke recurrence. Furthermore, anticoagulation 
significantly increases the risk of fatal and nonfatal hemorrhagic stroke and extracranial 
hemorrhage in these patients.1-3 However, warfarin clearly is indicated for patients who have 
embolic strokes caused by underlying conditions such as atrial fibrillation or myxoma. (Strength 
of recommendation: A) 
Evidence Summary 
Evidence-based guidelines recommend antiplatelet agents (e.g., aspirin) for most patients with 
noncardioembolic stroke and recommend warfarin for those with cardioembolic stroke. 
Researchers have wondered whether more aggressive anticoagulation also would benefit patients 
with noncardioembolic stroke. 
A Cochrane systematic review1 identified 11 randomized controlled trials (RCTs) with a 
combined 2,487 patients randomly assigned to receive anticoagulation (with warfarin or one of 
its analogues) or placebo after a presumed noncardioembolic ischemic stroke or transient 
ischemic attack. Nine of these trials were small and occurred before 1980 when computed 
tomography was not used routinely. Therefore, some initial hemorrhagic strokes possibly were 
included in the studies, and the lack of International Normalization Ratio (INR) monitoring of 
anticoagulation therapy in some studies may have contributed to an increased incidence of 
hemorrhage. The authors concluded that anticoagulation did not prevent recurrent ischemic 
stroke but that there was a significant increase in fatal intracranial hemorrhage (odds ratio [OR], 
2.54; 95% confidence interval [CI], 1.19 to 5.45; number needed to harm [NNH] = 50) and major 
fatal and nonfatal extracranial hemorrhage (OR, 3.43; 95% CI, 1.94 to 6.08; NNH = 20). 
Two studies not included in the above review have addressed some of these methodologic 
shortcomings. A large double-blinded RCT2 compared warfarin with aspirin for the prevention 
of recurrent ischemic stroke in 2,206 patients with a previous noncardioembolic stroke. The 
warfarin dosage was adjusted to produce an INR of 1.4 to 2.8, and aspirin was given at a fixed 
dosage of 325 mg per day. After two years there was no difference between warfarin and aspirin 
in the prevention of recurrent ischemic stroke or death or in the rate of major hemorrhage. The 
rate of recurrent stroke was 17.8 percent in patients receiving warfarin and 16.0 percent in those 
receiving aspirin. However, in the warfarin group, the median daily INR was 1.9, and 16.3 
percent of the daily INR values were less than 1.4. It is possible that any favorable or 
unfavorable treatment effects of warfarin were underestimated. 
A well-designed, double-blinded, multicenter RCT3 compared warfarin with aspirin in 569 
patients with symptomatic intracranial arterial stenosis. In this study, patients older than 40 years 
with transient ischemic attack or stroke caused by a moderate to severe stenosis (50 to 99 percent 
obstruction) of a major intracranial artery were randomly assigned to receive warfarin (with a 
target INR of 2 to 3) or 1,300 mg of aspirin per day. The primary end point was recurrent 
ischemic stroke, brain hemorrhage, or death from vascular causes other than stroke. With a mean 
follow-up period of 1.8 years, there was no difference in the likelihood of recurrent ischemic 
stroke, brain hemorrhage, or death from vascular causes other than stroke (21.1 percent in the 
aspirin group and 21.8 percent in the warfarin group). There also was no difference in the 
likelihood of recurrent ischemic stroke, ischemic stroke in the territory of the stenotic artery, and 
disabling or fatal ischemic stroke. However, compared with aspirin, warfarin significantly 
increased the risk of death (9.7 versus 4.3 percent; P = .02; NNH = 19) and major bleeding (8.3 
versus 3.2 percent; P = .01; NNH = 20). Therefore, warfarin is no more effective than aspirin in 
preventing recurrent stroke but causes a 
significantly higher number of adverse events. 
table 1 
Common Cardiac and Noncardiac Conditions 
Associated with Increased Risk of Embolism 
Cardiac 
Acute and subacute bacterial endocarditis 
Chronic atrial fibrillation 
Congenital heart defect (patent foramen ovale) 
Complication of cardiac surgery 
Myxoma 
Recent myocardial infarction with mural 
thrombus 
Valve prosthesis 
Valvular diseases (mitral stenosis, prolapsed 
Recommendations from Others 
The guideline for medical treatment for stroke 
prevention from the American College of 
Physicians4; the report of the Joint Stroke 
Guideline Development Committee of the 
American Academy of Neurology and the 
American Stroke Association5; the Seventh 
American College of Chest Physicians 
Conference on Antithrombotic and Thrombolytic 
Therapy6; and the guideline for prevention of 
stroke in patients with ischemic stroke or 
transient ischemic attack from the American 
Heart Association, American Stroke Association, and the American Academy of Neurology7 all 
recommend aspirin rather than warfarin to prevent recurrent stroke after a presumed 
noncardioembolic ischemic stroke. The latter guideline7 suggests that warfarin is an option in 
patients with a prothrombotic disorder, however. 
Clinical Commentary 
Making a clinical distinction between cardioembolic and noncardioembolic ischemic stroke can 
be difficult when no obvious risks or sources of embolism can be identified. The symptoms and 
signs of stroke are similar with embolic and thrombotic causes. However, the onset and 
progression of an embolic stroke generally are more rapid and without warning episodes. 
Therefore, it is imperative that physicians identify the presence of conditions that may increase 
the risk of embolism (Table 1) and initiate oral anticoagulation when cardioembolic stroke is 
suspected. For other noncardioembolic ischemic strokes, antiplatelet agents are recommended. 
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mitral valve) 
Noncardiac 
Atherosclerosis of aorta and carotid arteries 
Dissections and fibromuscular dysplasia of 
carotid and vertebral arteries 
Fat, tumor, or air embolism 
Thrombosis of the pulmonary veins 
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